Résumé
Cortisonic osteoporosis is a form of osteoporosis induced by the prolonged use of glucocorticoids, steroidal anti-inflammatory drugs such as cortisone. Although effective in treating chronic inflammatory diseases, these drugs can reduce bone density by disrupting calcium and phosphate metabolism. Glucocorticoids also deregulate the bone remodeling process, reducing bone formation and increasing bone resorption. As a result, bones become more fragile and subject to fracture, particularly in the vertebrae and wrist. Patients at risk are those taking high-dose corticosteroids for long periods (>7.5mg/d prednisone equivalent for at least three months). After diagnosis of osteoporosis and fracture risk, prevention and treatment of cortisone-induced osteoporosis generally involve calcium and vitamin D supplementation, bisphosphonates or teriparatide, as well as nonpharmacological measures such as physical activity and a balanced diet. Regular medical follow-up is essential to monitor the bone health of patients on corticosteroid therapy.